Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097403 - METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION

Publication Number WO/2020/097403
Publication Date 14.05.2020
International Application No. PCT/US2019/060367
International Filing Date 07.11.2019
IPC
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
C12N 5/0783 2010.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
A61K 31/454 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
445Non-condensed piperidines, e.g. piperocaine
4523containing further heterocyclic ring systems
454containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
Applicants
  • JUNO THERAPEUTICS, INC. [US]/[US]
Inventors
  • HASSKARL, Jens
  • FRANKEL, Stanley R.
  • PORTS, Michael
  • POURDEHNAD, Michael
  • JESSUP, Heidi
  • JIANG, Yue
  • QIN, Jim Shi Xiang
  • SONI, Neha
  • WORKS, Melissa
Agents
  • POTTER, Karen
  • CAO, Yuchen
  • POLIZZI, Catherine
Priority Data
62/757,75508.11.2018US
62/826,92829.03.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND COMBINATIONS FOR TREATMENT AND T CELL MODULATION
(FR) PROCÉDÉS ET COMBINAISONS POUR LE TRAITEMENT ET LA MODULATION DE LYMPHOCYTES T
Abstract
(EN)
The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents.
(FR)
La présente invention concerne, selon certains aspects, des procédés, des compositions et des utilisations impliquant des immunothérapies, telles qu'une thérapie cellulaire adoptive, par exemple, une thérapie par lymphocytes T, et un composé immunomodulateur, tel qu'un analogue ou un dérivé structural ou fonctionnel de la thalidomide et/ou un inhibiteur de l'E3-ubiquitine ligase. Les procédés, compositions et utilisations de l'invention comprennent ceux pour des polythérapies impliquant l'administration ou l'utilisation d'un ou de plusieurs composés immunomodulateurs conjointement avec une thérapie par lymphocytes T, tel qu'une thérapie par lymphocytes T génétiquement modifiés impliquant des cellules modifiées avec un récepteur recombinant, tel que des lymphocytes T exprimant un récepteur antigénique chimérique (CAR). Des compositions, des procédés d'administration à des sujets, des articles manufacturés et des kits utilisables dans lesdits procédés sont en outre décrits. Selon certains aspects, les caractéristiques des procédés et des cellules permettent une activité, efficacité, persistance, expansion et/ou prolifération accrues ou améliorées des lymphocytes T pour une thérapie cellulaire adoptive ou des lymphocytes T endogènes recrutés par des agents immunothérapeutiques.
Latest bibliographic data on file with the International Bureau